Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Written by Customer Service on June 3, 2023. Posted in Public Companies.

– Marked increases in overall survival observed across soft tissue sarcoma patients – – Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) – – DDLPS expansion cohort enrolling to inform a potential Phase 3 registration trial – SAN CARLOS, Calif., June 03, 2023 (GLOBE NEWSWIRE) — Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab (sotiga), Apexigen’s agonist antibody targeting CD40, in combination with standard-of-care doxorubicin (dox), in patients with...

Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO

Written by Customer Service on June 3, 2023. Posted in Public Companies.

Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3 June 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, is presenting today two posters at the 2023 American Society for Clinical Oncology meeting: A poster including an analysis of circulating tumor DNA (ctDNA) data from the Phase 3 KIMMTRAK (tebentafusp-tebn) trial in HLA-A*02:01 patients with metastatic uveal melanoma (mUM) A trial-in-progress poster describing the design of the Phase 2/3 trial with...

Cleantech Power Corp. Provides Update on Failure to File Cease Trade Order

Written by Customer Service on June 3, 2023. Posted in Public Companies.

TORONTO, June 02, 2023 (GLOBE NEWSWIRE) — Cleantech Power Corp. (formerly, Alkaline Fuel Cell Power Corp.) (the “Company” or “Cleantech”) (NEO: PWWR) (OTCQB: PWWRF) (Frankfurt: E43, WKN: A3EEHV), announces that further to its press release dated May 15, 2023, the British Columbia Securities Commission (the “BCSC”) has issued a failure to file cease trade order against the Company (“FTFCTO”) which orders that general trading, whether direct or indirect, by any person, of the securities of the Company cease, which includes trading of the shares of the Company on the NEO Exchange. The Company is diligently working with its auditors to conclude the filings at the earliest possible time. The delay in completing and filing the Company’s financial statements stems from certain accounting information that was required from Fuel Cell Power...

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30

Day: June 3, 2023